DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Long-Term Extension Study of WA22763 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Information source: Hoffmann-La Roche
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rheumatoid Arthritis

Intervention: tocilizumab [RoActemra/Actemra] (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: Hoffmann-La Roche

Official(s) and/or principal investigator(s):
Clinical Trials, Study Director, Affiliation: Hoffmann-La Roche

Summary

This multicenter, open-label, single arm, long-term extension study will evaluate the safety and efficacy of RoActemra/Actemra in patients with moderate to severe rheumatoid arthritis who have completed the 97-week WA22762 core study. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly for 104 weeks.

Clinical Details

Official title: A MULTICENTER, OPEN-LABEL LONG-TERM EXTENSION STUDY OF WA22762 TO EVALUATE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Long-term safety: Incidence of adverse events

Secondary outcome:

Change in disease activity: Disease Activity Score 28 - erythrocyte sedimentation rate (DAS28-ESR) and/or Simplified Disease Activity Index (SDAI)

Change in total tender joint count (TJC) / swollen joint count (SJC)

Proportion of patients with remission (DAS28 <2.6 or SDAI Proportion of patients with corticosteroid dose reductions and/or discontinuation

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Patients who have completed the 97-week WA22762 core study on subcutaneous or

intravenous RoActemra/Actemra and who experienced at any time during WA22762 clinically significant improvement in DAS28 (>1. 2 points), and based on the investigator's judgment may continue to benefit from RoActemra/Actemra treatment in this study investigating the subcutaneous formulation

- No current or recent adverse events or laboratory findings preventing the use of the

study drug dose of RoActemra/Actemra 162 mg sc at baseline visit

- Receiving treatment on an outpatient basis

- Females of childbearing potential and males with female partners of childbearing

potential must agree to use reliable means of contraception during the study and for at least 3 months following the last dose of study drug

- Oral corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS) up to the

recommended dose are permitted if on stable dose regimen for >/= 4 weeks prior to baseline

- Permitted non-biological disease-modifying anti-rheumatic drugs (DMARDs) are allowed

Exclusion Criteria:

- Patients who have prematurely withdrawn from the WA22762 core study for any reason

- Previous treatment with any cell-depleting therapies, including investigational

agents or approved therapies

- Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL)1 agent,

or a T-cell costimulation modulator since the last administration of study drug in the WA22762 core study

- Immunization with a live/attenuated vaccine since the last administration of study

drug in the WA22762 core study

- Diagnosis since last WA22762 visit (Week 97) of rheumatic disease other than

rheumatoid arthritis; secondary Sjörgen's syndrome with RA is permitted

- Diagnosis since last WA22762 visit (Week 97) of inflammatory joint disease other than

rheumatoid arthritis

- Uncontrolled disease states, such as asthma or inflammatory bowel disease, where

flares are commonly treated with oral or parenteral corticosteroids

- Evidence of serious uncontrolled concomitant disease

- Known active current or history of recurrent infection

- Primary or secondary immunodeficiency (history of or currently active)

- Body weight > 150 kg

- Pregnant or lactating women

- Inadequate hematologic, renal or liver function

Locations and Contacts

Bordeaux 33076, France

Montpellier 34295, France

Nantes 44035, France

Paris 75679, France

Strasbourg 67098, France

Toulouse 31059, France

Additional Information

Starting date: November 2012
Last updated: August 17, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017